Cerevel Therapeutics Holdings's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.55.
Cerevel Therapeutics Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.11.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Cerevel Therapeutics Holdings's Operating Cash Flow per Share or its related term are showing as below:
CERE'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -51.6 Med: -30.65 Max: -9.7
Current: -9.7
During the past 5 years, Cerevel Therapeutics Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was -9.70% per year. The lowest was -51.60% per year. And the median was -30.65% per year.
CERE's 3-Year OCF Growth Rate is ranked worse than 65.91% of 1229
companies
in the Biotechnology industry
Industry Median: 3.5
vs CERE: -9.70
Cerevel Therapeutics Holdings Operating Cash Flow per Share Historical Data
The historical data trend for Cerevel Therapeutics Holdings's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cerevel Therapeutics Holdings Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Operating Cash Flow per Share
-0.56
-1.60
-1.31
-1.94
-2.11
Cerevel Therapeutics Holdings Quarterly Data
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Operating Cash Flow per Share
-0.56
-0.61
-0.49
-0.46
-0.55
Competitive Comparison
For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerevel Therapeutics Holdings Price-to-Operating-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow falls into.
Cerevel Therapeutics Holdings Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Cerevel Therapeutics Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerevel Therapeutics Holdings Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERE has been successfully added to your 